Scope expanded with top 10 biopharma company

RNS Number : 3018J

IXICO plc

04 December 2018

 

4 December 2018

IXICO plc

("IXICO" or the "Company")

IXICO signs expanded scope to current contract with top 10 biopharmaceutical company

Increasing contract value by $2.4m over the remaining term

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces that it has signed an expanded scope to a current contract with a top 10 biopharmaceutical company. Additional services will be provided, increasing the value of the contract by $2.4m over the remaining 6-year term of the agreement. As a result, the contract value has increased from $2.7m to $5.1m.

The expanded scope will see IXICO providing additional imaging services, to a significantly higher number of patients, and an increased number of participating international study sites.

Giulio Cerroni, Chief Executive of IXICO, said: "I am delighted that our client has decided to expand our involvement in this important study. We value the strength of our relationships with biopharmaceutical companies and our ability to provide them with important insights that support their efforts to bring new therapies to market. This latest increase in scope demonstrates IXICO's ability to efficiently scale operations and adapt to changing requirements as global clinical studies progress."

For further information please contact:

IXICO plc Giulio Cerroni, Chief Executive Officer Susan Lowther, Chief Financial Officer	Tel: [phone]
Shore Capital (Nomad and Broker) Edward Mansfield/Anita Ghanekar/Daniel Bush	Tel: [phone]
FTI Consulting Limited (Investor Relations) Simon Conway/Mo Noonan	Tel: [phone]

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel medical imaging and mobile health digital technologies.

IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.

More information is available on www.IXICO.com

 

END

 

 

CNTFSUFUDFASEEE